ERBB2 and breast cancer: Identification of HER2+ CTCs, as defined by expression of HER2 mRNA derived from CTCs, was also associated with shorter disease free survival (DFS) in a cohort of early breast cancer patients, although this did not remain an independent prognostic factor in a multivariate analysis, nor was there any significant association with OS [61].